(Q38192049)

30 August 2017

1 reference

title

Metformin in the treatment of non-alcoholic fatty liver disease: safety, efficacy and mechanism (English)

1 reference

metabolic dysfunction–associated steatotic liver disease

30 August 2017

1 reference

1 reference

based on heuristic

inferred from title

non-alcoholic fatty liver

1 reference

1 reference

Samir Rouabhia

1

1 reference

PubMed ID

24580044

30 August 2017

Natasa Milic

series ordinal

2

1 reference

PubMed ID

24580044

30 August 2017

Ludovico Abenavoli

series ordinal

3

1 reference

30 August 2017

3 March 2014

1 reference

Expert Review of Gastroenterology & Hepatology

30 August 2017

1 reference

30 August 2017

8

1 reference

30 August 2017

343-349

1 reference

30 August 2017

4

1 reference

Non-alcoholic fatty liver disease: the mist gradually clears

30 August 2017

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.894880

Nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.894880

Systematic review with meta-analysis: non-alcoholic steatohepatitis - a case for personalised treatment based on pathogenic targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.894880

Systems biology elucidates common pathogenic mechanisms between nonalcoholic and alcoholic-fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.894880

Non-alcoholic fatty liver and insulin resistance: a cause-effect relationship?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.894880

Approach to the pathogenesis and treatment of nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.894880

Metformin and its clinical use: new insights for an old drug in clinical practice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.894880

Review article: Drug therapy for non-alcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.894880

Metformin reverses fatty liver disease in obese, leptin-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.894880

Metformin prevents and reverses inflammation in a non-diabetic mouse model of nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.894880

Metformin in non-alcoholic steatohepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.894880

Clinical trial: pilot study of metformin for the treatment of non-alcoholic steatohepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.894880

Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.894880

Metformin in the treatment of patients with non-alcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.894880

Metformin versus dietary treatment in nonalcoholic hepatic steatosis: a randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.894880

The effect of metformin on leptin in obese patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.894880

Metformin in patients with non-alcoholic fatty liver disease: a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.894880

The Effect of Metformin and Standard Therapy versus Standard Therapy alone in Nondiabetic Patients with Insulin Resistance and Nonalcoholic Steatohepatitis (NASH): A Pilot Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.894880

Relation between augmentation index and adiponectin during one-year metformin treatment for nonalcoholic steatohepatosis: effects beyond glucose lowering?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.894880

Treatment with insulin sensitizer metformin improves arterial properties, metabolic parameters, and liver function in patients with nonalcoholic fatty liver disease: a randomized, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.894880

A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.894880

Efficacy of insulin-sensitizing agents in nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.894880

Effects of metformin, pioglitazone, and silymarin treatment on non-alcoholic Fatty liver disease: a randomized controlled pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.894880

Metformin--the gold standard in type 2 diabetes: what does the evidence tell us?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.894880

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.894880

Lactic acidosis rates in type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.894880

A review of the efficacy and safety of oral antidiabetic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.894880

Metformin: an old but still the best treatment for type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.894880

Metformin in non-alcoholic steatohepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.894880

Mechanisms involved in the protective effects of metformin against nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.894880

Metabolic effects of metformin in non-insulin-dependent diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.894880

The role of metformin in the management of NAFLD

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.894880

Multidisciplinary pharmacotherapeutic options for nonalcoholic Fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.894880

Nonalcoholic Fatty liver: a possible new target for type 2 diabetes prevention and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.894880

Insulin sensitisers in the treatment of non-alcoholic fatty liver disease: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.894880

Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.894880

Clinical trial: insulin-sensitizing agents may reduce consequences of insulin resistance in individuals with non-alcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.894880

The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.894880

Characteristics and diagnosis of NAFLD/NASH.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.894880

Non-alcoholic fatty liver disease: factors associated with its presence and onset

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.894880

Effects of losartan and amlodipine alone or combined with simvastatin in hypertensive patients with nonalcoholic hepatic steatosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.894880

Ultrasonography modifications of visceral and subcutaneous adipose tissue after pioglitazone or glibenclamide therapy combined with rosuvastatin in type 2 diabetic patients not well controlled by metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.894880

10.1586/17474124.2014.894880

21 January 2018

Identifiers

DOI

1 reference

30 August 2017

1 reference

PubMed ID

24580044